News Focus
News Focus
icon url

Gman24

04/01/17 4:40 PM

#248883 RE: namtae #248882

Yeah it would be just awful if Elite had to share this space with another Pharma in this 17-20 billion dollar market. ( said no one ever)
icon url

Couch

04/01/17 4:57 PM

#248886 RE: namtae #248882

LMFAO- ELTP's PPS isn't going to move in relation to another company one way or another.

BE data coming in MAY - TIME TO LOAD THE ELTP BOAT - FURTHER

Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study For Reformulated SequestOx™

NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its reformulated SequestOx™. The reformulated product is expected to have a shorter Tmax under fed conditions. Elite is conducting a bioequivalence study which is a pivotal, open-label, randomized, single-dose, three-way, crossover study to evaluate the relative comparative bioavailability and bioequivalence of the modified formulation of SequestOx™ to the original formulation of SequestOx™ and to a comparator product under fed conditions. The study has enrolled forty-five healthy volunteers and the first subjects have been dosed.

SequestOx™ is Elite's investigational immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

"We are pleased to have this bioequivalence study underway for SequestOx™," commented Nasrat Hakim, President and CEO of Elite. "We are expecting results for this study by the middle of May and re-submitting the NDA prior to the end of the year."
icon url

newguy11

04/01/17 7:17 PM

#248893 RE: namtae #248882

Hope you can get people to follow your advice, I'm always looking for cheaper shares..